TY  - JOUR
A1  - Bolm, Louisa
A1  - Zemskov, Sergii
A1  - Zeller, Maria
A1  - Baba, Taisuke
A1  - Roldan, Jorge
A1  - Harrison, Jon M.
A1  - Petruch, Natalie
A1  - Sato, Hiroki
A1  - Petrova, Ekaterina
A1  - Lapshyn, Hryhoriy
A1  - Braun, Ruediger
A1  - Honselmann, Kim C.
A1  - Hummel, Richard
A1  - Dronov, Oleksii
A1  - Kirichenko, Alexander V.
A1  - Klinkhammer-Schalke, Monika
A1  - Kleihues-van Tol, Kees
A1  - Zeissig, Sylke R.
A1  - Rades, Dirk
A1  - Keck, Tobias
A1  - Fernandez-del Castillo, Carlos
A1  - Wellner, Ulrich F.
A1  - Wegner, Rodney E.
T1  - Concepts and outcomes of perioperative therapy in stage IA-III pancreatic cancer — a cross-validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT)
JF  - Cancers
N2  - (1) Background: The aim of this study is to assess perioperative therapy in stage IA-III pancreatic cancer cross-validating the German Cancer Registry Group of the Society of German Tumor Centers — Network for Care, Quality, and Research in Oncology, Berlin (GCRG/ADT) and the National Cancer Database (NCDB). (2) Methods: Patients with clinical stage IA-III PDAC undergoing surgery alone (OP), neoadjuvant therapy (TX) + surgery (neo + OP), surgery+adjuvantTX (OP + adj) and neoadjuvantTX + surgery + adjuvantTX (neo + OP + adj) were identified. Baseline characteristics, histopathological parameters, and overall survival (OS) were evaluated. (3) Results: 1392 patients from the GCRG/ADT and 29,081 patients from the NCDB were included. Patient selection and strategies of perioperative therapy remained consistent across the registries for stage IA-III pancreatic cancer. Combined neo + OP + adj was associated with prolonged OS as compared to neo + OP alone (17.8 m vs. 21.3 m, p = 0.012) across all stages in the GCRG/ADT registry. Similarly, OS with neo + OP + adj was improved as compared to neo + OP in the NCDB registry (26.4 m vs. 35.4 m, p < 0.001). (4) Conclusion: The cross-validation study demonstrated similar concepts and patient selection criteria of perioperative therapy across clinical stages of PDAC. Neoadjuvant therapy combined with adjuvant therapy is associated with improved overall survival as compared to either therapy alone.
KW  - pancreatic cancer
KW  - perioperative therapy
KW  - neoadjuvant therapy
KW  - pancreatic surgery
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262174
SN  - 2072-6694
VL  - 14
IS  - 4
ER  -